증례 : 만성 골수성 백혈병에서 항암제 투여로 호전된 음경지속발기증 1 예

김예희 ( Re Hwe Kim ),이오정 ( Oh Jung Lee ),박현아 ( Hyun Ha Park ) 대한내과학회 1981 대한내과학회지 Vol.24 No.4

폐에 생긴 점액표피양 암종 2예

김준희 ( Joon Hee Kim ),김용복 ( Yong Bok Kim ),김철수 ( Chul Soo Kim ),김동순 ( Dong Soon Kim ),김예희 ( Re Hwe Kim ),김창호 ( Chang Ho Kim ),서연림 ( Yeon Lim Suh ) 대한결핵 및 호흡기학회 1993 Tuberculosis and Respiratory Diseases Vol.40 No.1

진행된 유암환자에서 내분비요법과 화학요법의 동시시행 (pp.332-335)

김관엽 ( Kwan Yop Kim ),이석호 ( Suck Ho Lee ),임성손 ( Sung Son Lim ),김예희 ( Re Hwe Kim ) 대한내과학회 1979 대한내과학회지 Vol.22 No.4

악성종양에 대한 Adriamycin 의 임상효과

강성구 ( Sung Koo Kang ),김예희 ( Re Hwe Kim ),김재형 ( Jae Hyung Kim ),정태준 ( Tae June Chung ) 대한내과학회 1975 대한내과학회지 Vol.18 No.3

진행된 위암에서 Ftorafur 및 CCNU의 병용요법

김관엽 ( Kwan Yop Kim ),이오정 ( Oh Jeong Lee ),김예희 ( Re Hwe Kim ),김명진 ( Myung Jin Kim ) 대한내과학회 1981 대한내과학회지 Vol.24 No.7

Indomethacin이 흰쥐의 Bleomycin에 의한 폐섬유증발생에 미치는 효과

김동순 ( Dong Soon Kim ),염호기 ( Ho Kee Yeom ),김예희 ( Re Hwe Kim ),함의근 ( Euy Geun Ham ) 대한결핵 및 호흡기학회 1988 Tuberculosis and Respiratory Diseases Vol.35 No.4

위암의 간문맥 전이로 발생한 악성 폐쇄성 황달에 대한 외부 방사선치료 효과

양광모(Kwang Mo Yang),김준희(Joon Hee Kim),김철수(Chul Soo Kim),시현숙(Hyun Suk Suh),김예희(Re Hwe Kim) 대한방사선종양학회 1995 Radiation Oncology Journal Vol.13 No.4

목적 : 위암의 간문맥 임파절 재발로 발생한 악성 폐쇄성 황달치료에 있어서 외부 방사선치료의 효과를 평가해 보고 치료의 결과에 영향을 미칠 수 있는 요인을 알아보고자 하였다. 방법 : 1984년부터 1993년까지 위암의 간문맥 전이로 악성 폐쇄성 황달이 발생한 32명중 3000cGy이상의 방사선량이 조사된 23명을 대상으로 하였다. 치료 결과에 영향을 미칠 수 있는 요인을 알아보기 위하여 방사선량, 황달발생 당시의 질병의 진전정도 및 황달을 일으키는 종괴의 위치, 방사선치료 전 총 bilirubin치, 다른 치료와의 병합여부, 원발병소의 수술정도, 재발전 병기를 분석하였다. 외부 방사선치료는 4백만 전자볼트 선형가속기를 이용하여 주 5회, 1회 180-300cGy를 간문맥을 포함하는 부위에 3000cGy-5480cGy(중앙값 3770cGy, TDF 49-86 3420cGy-5580cGy 중앙값 TDF 65, 4140cGy/23fx)가 조사되었다. TDF 65(4140cGy/23fx) 이상과 미만을 받은 환자는 각각 13, 10명이었다. 결과 : 전체 환자 32명중 완전관해 13명, 부분관해 5명, 무반응 5명이었다. 전체 환자의 종양 생존 기간은 5개월이나 완전관해의 경우는 11개월이고 부분관해와 무반응의 경우 각각 3개월이었다. 완전관해를 보인 13명중 6명이 1년 이상 생존하였다. 완전관해의 경우와 부분관해, 무반응과의 생존 기간의 비교에서 의미있는 차이를 보였다(p Purpose : Since 1983, authors have conducted a study to evaluate the effect of external radiation therapy and to determine affected factors in management of the patients with malignant obstructive jaundice due to porta hepatis metastasis from stomach cancer. Materials and Methods : Thirty two patients with malignant obstructive jaundice due to porta hepatis metastasis from gastric cancer were presented. We have analysed 23 patients who were treated with external radiation therapy of more than 3000cGy. The radiation dose, disease extent at development of jaundice, total bilirubin levels before radiation therapy. initial stage of gastric cancer were analyzed to determine affected factors in radiation therapy. External radiation therapy was delivered with a daily dose of 180-300cGy. 5 times a week fractionation using 4 MeV linear accelerator. The radiation field included the porta hepatis with tumor mass received more than 3000cGy. total irradiation dose was ranged from 3000cGy to 5480cGy. median 3770cGy. Among 23 patients, 13 patients were delivered more than equivalent dose of TDF 65(4140cGy/23fx). Results : Among 23 patients, complete, partial and no response were observed in 13, 5, 5 patients, respectively. The median survival for all patients was 5 months. The significant prolongation of median survival was observed in complete responder(11 months) as compared to partial and no responders(5 months, 5 months, respectively). Out of 13 patients with complete response, 6 patients lived more than a year. Among 13 patients receiving more than 4140cGy equivalent dose, complete, partial and no response were observed in 10.2 and 1 patients, respectively. The median survival for all these patients was 9.5 months. The median survival for complete responders(10/13) was 11.5 months. Among 10 patients receiving less than 4140cGy equivalent dose, complete, partial and no response were observed in 3, 3, 4 patients. respectively. The median survival for all these patients was 4.3 months. therefore, the radiation dose affected the results of treatment. For the complete response with prolongation of survival duration, at least 4140cGy equivalant dose should be delivered to porta hepatis. In valuation of the disease extent, 7 patients of 13 complete responders showed localized disease in porta hepatis or peripancreatic area, but all patients with partial and no response showed wide extensive disease or persistant disease of primary gastric cancer. Therefore, the patients with the localized disease were the higher probability of complete response and long term survival. This study suggested that the radiation dose and the disease extent at development of jaundice affected in radiation therapy for malignant obstructive jaundice. There were no serious complications related to external radiation therapy. Conclusion : External radiation therapy only could achieve the palliative effect in the patients with malignant obstrctive jaundice due to porta hepatis metastasis from stomach cancer. This study suggested that the prolongation of survival duration could be acheived in complete responders and radiation dose. extent of disease affected the results of treatment of malignant obstructive jaundice

진행성 비소세포 폐암에 대한 5 - Fluorouracil , Vinblastine 과 Cisplatin ( FVP ) 의 복합화학요법

최홍집(Hong Jib Choi),김성록(Sung Rok Kim),양성현(Sung Hyun Yang),최수전(Soo Jeon Choi),김철수(Chul Soo Kim),김예희(Re Hwe Kim) 대한내과학회 1997 대한내과학회지 Vol.53 No.1

N/A The 5 year survival rate after surgical resection for stage III non-small cell lung cancer(NSCLC) remains short, only 10-19%. Radiotherapy seems to show some benefit for local control, but it does not reflect to prolongation of survival, as distant metastasis prevails. Vinblastine is one of the most active agent against NSCLC. 5-Fluorouracil(5-FU) and cisplatin are synergistic in anti-cancer activity in adenocarcinoma of gastrointestinal tract and squamous cell cancer of head and neck. We initiated a phase II trial for advanced NSCLC to determine the effect of FVP regimen in response rate, survival and toxicities. The therapy consisted of 5-FU 500mg/m2/12 hours continious IV infusion for 36 hours from day 1, vinblastine 3mg/m2 IV bolus day 1 and 2, cisplatin 75mg/m2 IV infusion over 2 hours day 1 and it was repeated every 3 weeks. Among the 45 patients entered into this study, 40 patients were evaluable for response. The objective response rate was 50%(CR;1/40, 2.5% PRi19/40, 47.5%). The median survival of all the patients was 42.9 weeks(8.4+ - 140.6 weeks); the responding patients survived longer than the non-responders(mediansurvival; 54.4 weeks vs 29.7 weeks, p<0.05). The toxicities of this regimen were acceptable but 1 patient died of pneumonia associated with granulocytopenia. We concluded that the FVP regimen is effective in the treatment of advanced non-small cell lung cancer and a prospective randomized trial and long- term follow up is warranted.

식도암의 방사선-항암화학 병용치료결과

이현주(Hyun Joo Lee),서현숙(Hyun Suk Suh),김준희(Jun Hee Kim),김철수(Chul Soo Kim),김성록(Sung Rok Kim),김예희(Re Hwe Kim) 대한방사선종양학회 1996 Radiation Oncology Journal Vol.14 No.1

목 적 : 외과적 절제가 불가능하거나 내과적인 문제로 수술을 받을 수 없는 식도암환자에서 방사선-항암화학 병용치료를 시행하였으며 이를 방사선 단독치료군의 치료결과와 후향적으로 비교 분석하였다. 대상 및 방법 : 1983년 10월부터 1994년 12월까지 인제대학교부속 백병원 치료방사선과에서 식도암으로 치료받은 환자 64명중 추적관찰이 가능하였던 55명을 대상으로하였다. 이중 방사선-항암화학 병용치료군은 30(A군), 방사선 단독치료군 25명(B군)이었다. 외부방사선치료는 4 MV 선형가속기를 이용하여 식도의 원발병소와 인접 림프절을 포함하는 조사야로 치료하였고, 조사선량은 2520-6490cGy(중앙값 5460cGy), 180-200cGy/fx으로 주었다. 항암화학요법은 방사선치료전 또는 후에 총 1-13회(중앙값 2회)가 시행되었도, 연령 및 성별분포는 두 군에서 유사하였고, 병리 조직학적 소견상 50명이 편평상괴암이었다. 진단당시 병기별분포(1983년 AJCC)는 병기 I, II, III가 각각 A군 1, 5, 24명, B군 1, 8, 16명이었다. 종괴크기에따라 5cm미만과 5cm이상이 각각 A군 5, 25명, B군 3, 22명이었다. 총 조사선량은 50Gy미만과 50Gy이상이 각각 A군 14, 16명, B군 11, 14명이었다. 두 군의 치료결과 비교 및 각군에서의 예후인자를 알아보기 위하여 병기, 종괴의 크기, 조사선량에 따라 1년 및 2년 생존율을 구하였다. 결 과 : 총 추적관찰기간은 2-73개월(중앙값 7개월)이었다. 환자의 중앙생존기간은 A군 7.5 개원(20-29개월), B군 5개월(20-73개월)이었으며, 1, 2 생존율(YSR)은 각각 A군 26.7%, 8.9%, B궁 12.7%, 4.3% (p>0.05)였다. 병기 III에서 1YSR은 A군 24.9% (2YSR 0%) B군 13.7 (2YSR 6.9%)였고, 종괴크기 5cm미만과 이상에서 1YSR은 A군 60.0%, 17.4% (2YSR 8.0%, 3.5%) B군 0%, 14.5% (2YSR 0%, 4.8%)였다. 조사선량 50Gy이상과 미만에 따라 1YSR이 31.2%, 21.5% (2YSR 6.2%, 7.2%) B군 23.0%, 0% (2YSR 7.7%, 0%)였다. 두 군의 1, 2YS을 진행된 식도암의 경우에서 병기 III, 종괴크기 5cm이상, 조사선량 50Gy이상을 받은 환자를 대상으로 비교분석한 결과 통계학적으로 유의한 차이를 보이지 않았다. 방사선치료후 치료반응을 판정 할 수 있었던 28명에서 완전관해는 A군 4명, B군 1명이었고 전체관해율은 각각 43.8%(7/16), 25.0%(3/12)로 나타났다. 치료실패양상을 분석할 수 있었던 35명중 국소실패는 A군과 B군에서 각 각 52.4%(11/21), 64.3%(9/14), 원격전이는 각각 23.8%(5/21), 14.3%(2/14), 동시재발이 각 각 23.8%(5/21), 21.4%(3/14)였다. 치료에 따른 급성부작용은 병용치료군이 단독치료균에 비해 백혈구감소증과 오심구토의 빈도가 증가하였으나 정도의 차이는 크지 않았다. 결 론 : 진행된 병기의 식도암환자에서 방사선-항암화학병용치료를 시행함으로써 별다른 부작용 없이 생존기간 및 1년/2년 생존율을 향상시킬 수 있음을 관찰하였으나 통계학적으로 유의한 차이는 없었다. 방사선치료 단독군에서 총 방사선조사량만이 예후인자로써 확인되었다. Purpose : To evaluate the role of combination therapy of external radiotherapy and chemotherapy in the management of advanced esophageal cancer as a primary treatment compared with radiation therapy alone. Materials and Methods : A retrospective review of evaluable 55 esophageal cancer patients referred to the Department of Therapeutic Radiology, Paik Hospital for the external radiotherapy between Jul, 1983 and Dec. 1994 was undertaken. Combined therapy patients (A group) were 30 and radiation alone patients (B group) were 25. Median age was 60 years old in A group (ranges : 42-81) and 65 years old in B group (ranges : 50-81). The male patients were 53. The fifty patients had squamous cell carcinomas. Radiation doses of 2520-6480cRy were delivered over a period of 4-7weeks, using 4MV LINAC. Chemotherapy was administered in bolus injection before, after, or during the course of external radiotherapy. The local control rate and patterns of failure according to both treatment modalities and 1, 2 year survival rates according to prognostic factors (stage, tumor length, radiation dose etc.) were analysed. Resuts : Median follow up period was 7 months (range : 2-73 months). Median survival was 7.5 months (20 days-29 months) in A group and 5 months (20 days-73 months) in B group. The 1, 2 YSRs were 26.7%, 8.9%, in A group, 12.7%, 4.3% in B group (p>0.05), respectively. The 1, 2 YSRs according to stage(II/III), tumor length (5cm more or less), radiation dose (5000cGy more or less) of A and B group were analyzed and the differences of survival rates of both treatments were not statistically significant. But among group B, patients who received 5000cGy or more showed significant survival benefits (p

류마티스 관절염 양상으로 발현한 다발성 골수종에 의한 아밀로이드 관절병증

한성훈 ( Seong Hoon Han ),양대원 ( Dae Won Yang ),김동욱 ( Dong Yook Kim ),김준희 ( Joon Hee Kim ),신보문 ( Bo Moon Shin ),이윤우 ( Yun Woo Lee ),김예희 ( Re Hwe Kim ) 대한류마티스학회 1998 대한류마티스학회지 Vol.5 No.2

Amyloid arthropathies in patients with multiple myeloma have been reported rarely in the world. In Korea, only one case of amyloid arthropathy with multiple myeloma was reported, but there had been no report of multiple myeloma which was initially manifested as a polyarthritis simulating rheumatoid arthritis. We report a case of multiple myeloma with amyloid arthropathy. The patient was 62 years old man, who had had progressive bilateral shoulder pain for one year. Since 6 months prior to admission, progressive painful swelling developed in bilateral hips, shoulders, wrists and hands. Simple X-rays and MRI of shoulders and hips showed huge osteolytic mass, and the amyloid was found in the biopsy of the mass in hip. The diagnosis of multiple myeloma was made after bone marrow biopsy and biochemical studies, but X-rays of skeletal survey didn`t show typical osteolytic lesions of multiple myeloma at the time of diagnosis.